News & Updates

Early diabetic polyneuropathy signals subsequent CVD

17 Jun 2021

Among patients with newly diagnosed type 2 diabetes, the risk of developing cardiovascular disease (CVD) is elevated in the presence of symptoms indicative of diabetic polyneuropathy, as shown in a study.

Early diabetic polyneuropathy signals subsequent CVD

17 Jun 2021

Obesity fuels blood glucose spikes in nondiabetic pregnant women

16 Jun 2021

Obesity raises glycaemic level in pregnant women even if they have normal findings on a glucose tolerance test (OGTT), a recent study has found.

Obesity fuels blood glucose spikes in nondiabetic pregnant women

16 Jun 2021

Ulipristal acetate vs GnRH agonist: which is more liver-friendly?

16 Jun 2021

The incidence of severe liver disease, hepatic failure, and toxic liver disease is comparable between ulipristal acetate and (UPA) gonadotropin-releasing hormone (GnRH) agonists, reports a recent study. However, patients on UPA have a higher rate of mild liver disease than those in the GnRH agonist group.

Ulipristal acetate vs GnRH agonist: which is more liver-friendly?

16 Jun 2021

Immune activation profiles may hint at insulin resistance, MetS

16 Jun 2021

A specific profile of immune activation (IA)—characterized by CD4+ T cell senescence, inflammation, and endothelial, monocyte, and B cell activation—seems to be linked to insulin resistance (IR) and metabolic syndrome (MetS), a recent study has found.

Immune activation profiles may hint at insulin resistance, MetS

16 Jun 2021

High dietary GI, GL intakes nix weight management in overweight, obese adults

16 Jun 2021

Increased consumption of foods with high glycaemic index (GI) and load (GL) leads to weight regain and glycaemic status worsening in overweight or obese individuals undergoing weight loss maintenance (WLM), a study has found.

High dietary GI, GL intakes nix weight management in overweight, obese adults

16 Jun 2021

Metformin reduces risk of BCC development

15 Jun 2021

Treatment with metformin, even at low doses, appears to lower the risk of basal cell carcinoma (BCC) development, results of a recent study have shown.

Metformin reduces risk of BCC development

15 Jun 2021

Lower LDL-C levels linked to decreased insulin secretion

15 Jun 2021 by

Insulin secretion is reduced in case of lesser low-density lipoprotein cholesterol (LDL-C), which possibly explains the deteriorated glycaemic control in response to cholesterol-lowering drugs, suggests a study.

Lower LDL-C levels linked to decreased insulin secretion

15 Jun 2021

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

15 Jun 2021

New drug applications approved by US FDA as of 01-15 June 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

15 Jun 2021

Henagliflozin-metformin combo a new therapeutic alternative for T2D

14 Jun 2021 by

Adding the sodium-glucose cotransporter-2 (SGLT2) inhibitor henagliflozin to metformin led to significant improvements in glycaemic control, body weight, and blood pressure (BP) in Chinese patients with type 2 diabetes (T2D) with insufficient response to metformin alone, a phase III study has shown.

Henagliflozin-metformin combo a new therapeutic alternative for T2D

14 Jun 2021

Maternal stroke history tied to haemorrhagic stroke risk in T1D patients

13 Jun 2021

Patients with type 1 diabetes (T1D) born to mothers with a history of stroke are at heightened risk of developing haemorrhagic stroke, a study reports.

Maternal stroke history tied to haemorrhagic stroke risk in T1D patients

13 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Early diabetic polyneuropathy signals subsequent CVD

Early diabetic polyneuropathy signals subsequent CVD

Obesity fuels blood glucose spikes in nondiabetic pregnant women

Obesity fuels blood glucose spikes in nondiabetic pregnant women

Ulipristal acetate vs GnRH agonist: which is more liver-friendly?

Ulipristal acetate vs GnRH agonist: which is more liver-friendly?

Immune activation profiles may hint at insulin resistance, MetS

Immune activation profiles may hint at insulin resistance, MetS

High dietary GI, GL intakes nix weight management in overweight, obese adults

High dietary GI, GL intakes nix weight management in overweight, obese adults

Metformin reduces risk of BCC development

Metformin reduces risk of BCC development

Lower LDL-C levels linked to decreased insulin secretion

Lower LDL-C levels linked to decreased insulin secretion

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

Henagliflozin-metformin combo a new therapeutic alternative for T2D

Henagliflozin-metformin combo a new therapeutic alternative for T2D

Maternal stroke history tied to haemorrhagic stroke risk in T1D patients

Maternal stroke history tied to haemorrhagic stroke risk in T1D patients